Brokerages Expect Ultragenyx Pharmaceutical (RARE) to Post -$0.76 EPS

Brokerages expect Ultragenyx Pharmaceutical (NASDAQ:RARE) to report ($0.76) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at $0.91 and the lowest estimate coming in at ($2.20). Ultragenyx Pharmaceutical posted earnings per share of ($1.63) during the same quarter last year, which would indicate a positive year-over-year growth rate of 53.4%. The firm is expected to announce its next quarterly earnings report on Thursday, May 3rd.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($6.14) per share for the current fiscal year, with EPS estimates ranging from ($8.73) to ($2.54). For the next fiscal year, analysts forecast that the company will report earnings of ($6.69) per share, with EPS estimates ranging from ($8.74) to ($5.20). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Ultragenyx Pharmaceutical.

How to Become a New Pot Stock Millionaire

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.00) by ($0.27). The business had revenue of $2.41 million during the quarter, compared to the consensus estimate of $0.75 million. During the same quarter in the previous year, the company posted ($1.75) EPS.

RARE has been the topic of a number of analyst reports. Evercore ISI upgraded Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating in a research note on Monday, January 22nd. Zacks Investment Research cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. Credit Suisse Group initiated coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, January 17th. They issued an “outperform” rating and a $67.00 price target on the stock. Stifel Nicolaus restated a “buy” rating and issued a $74.00 price target (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Finally, BidaskClub cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $69.41.

Several institutional investors and hedge funds have recently bought and sold shares of RARE. First Trust Advisors LP increased its position in shares of Ultragenyx Pharmaceutical by 49.4% during the fourth quarter. First Trust Advisors LP now owns 785,694 shares of the biopharmaceutical company’s stock worth $36,440,000 after purchasing an additional 259,816 shares in the last quarter. Pier Capital LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $5,831,000. Hudson Bay Capital Management LP purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $4,638,000. Opaleye Management Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $4,174,000. Finally, Alliancebernstein L.P. grew its holdings in shares of Ultragenyx Pharmaceutical by 8.7% during the fourth quarter. Alliancebernstein L.P. now owns 700,406 shares of the biopharmaceutical company’s stock worth $32,485,000 after buying an additional 56,106 shares during the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.

Ultragenyx Pharmaceutical stock traded up $0.97 during midday trading on Thursday, reaching $54.79. The company’s stock had a trading volume of 829,243 shares, compared to its average volume of 553,407. Ultragenyx Pharmaceutical has a fifty-two week low of $41.67 and a fifty-two week high of $71.99. The stock has a market cap of $2,635.06, a PE ratio of -7.31 and a beta of 1.82.

TRADEMARK VIOLATION NOTICE: This news story was first published by registrarjournal.com and is the property of of registrarjournal.com. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://registrarjournal.com/2018/04/17/brokerages-expect-ultragenyx-pharmaceutical-rare-to-post-0-76-eps.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply